Connect with us

Hi, what are you looking for?

Jewish Business News


CollPlant Tests New Treatment for Chronic Wounds


Israel’s CollPlant, which develops and manufactures human collagen-based medical products, has treated the first patient in its VergenixFG clinical trial in Israel.

The VergenixFG gel is an advanced gel formulation based on rhCollagen, intended for chronic wounds including diabetic foot ulcers, pressure and venous ulcers, and surgical and trauma wounds. The product is based on a human collagen produced in tobacco plants using a patented technology owned by CollPlant.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

The company said that the objective of the trial is to evaluate the safety of the product, and its performance on patients suffering from lower limb chronic wounds. The effectiveness of the treatment will be primarily assessed by the percentage of wound closure. The trial is expected to spread over a few months and will take place at three wounds clinics of one of the leading HMOs in Israel. Twenty patients suffering from lower limb chronic wounds will receive one-time treatment with the product. Each patient will be monitored over 4 weeks.
The Company plan is to commence sales of the product in Europe in 2015, and accordingly CollPlant is in dialog with international partners for distribution in Europe. The advanced wound care market, for which this product is intended, is estimated at USD 5 billion.

Yehiel Tal, CEO of CollPlant, said, “We are very pleased to be commencing the clinical trial of VergenixFG which is based on a unique technology that has the potential to significantly improve the quality of life outcomes for patients with lower limb chronic wounds. The trial is a major milestone in our plan to commercialize the Company’s products in global markets. The product provides a solution for the urgent and vital need to be able treat patients with chronic wounds. In parallel with the start of the trial, we are now preparing to apply for the CE Mark for marketing the product in Europe”

Based in Rehovot, CollPlant is a medical device firm established in 2004 to focus on advancing regenerative medicine through its cutting-edge technology designed to generate and process proprietary recombinant human collagen, among other patent-protected recombinant proteins. CollPlant is developing a broad spectrum of biomaterials for a wide variety of medical markets, including orthopedics, wound healing, and general surgery.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.